The goal is to establish the effect of oral inulin supplementation on continuous glucose monitoring (CGM) metrics and immunological parameters in adults with type 1 diabetes. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x38 participants to measure effects on CGM metrics, gut microbiome composition, residual beta cell and immunological parameters.
The investigators perform a double-blind, randomized, placebo-controlled trial in 2x38 adults with type 1 diabetes. The participants will be given inulin or placebo once daily in powder, which can be dissolved in water and ingested orally, for 90 days. The main study endpoint is the difference in time in range between the groups between baseline and end-of-study. Secondary endpoints include changes in glycaemic variability, time in tight glycaemic range and hypoglycaemic episodes, gut microbiome composition, changes in residual beta cell function, changes in immunological parameters and validated questionnaires (Quality of Life and gastro-intestinal complaints).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
76
inulin (prebiotic, fermentable fiber)
placebo (matodextrin)
Diabeter Centrum Amsterdam
Amsterdam, Netherlands
RECRUITINGAmsterdam UMC
Amsterdam, Netherlands
RECRUITINGTime in range
Difference in time in range between the groups between baseline and end-of-study
Time frame: 90 days
Continuous glucose monitoring
changes in glycaemic variability, time above range, time below range and hypoglycaemic episodes
Time frame: 90 days
Gut microbiome composition
Time frame: 90 days
Residual beta cell function
Changes in urinary C-peptide-to-creatinine-ratio (UCPCR)
Time frame: 90 days
Immunological parameters
Plasma cytokines IFN-α, IFN-β, IFN-γ, IL-10 by ELISA
Time frame: 90 days
Gastrointestinal Symptom Rating Scale (GSRS)
Questionnaire. The minimum and maximum score are 15 and 105 points respectively, and a higher score in the scale reflects more gastro-intestinal complaints.
Time frame: 90 days
Dietary intake
Recorded of 3 days with "Eetmeter".
Time frame: 90 days
Gut inflammation
Fecal IgA and calprotectin in ug/g
Time frame: 90 days
CRP
C-reactive protein (mg/L)
Time frame: 90 days
Leukocyte (differentation)
×10 9 /L
Time frame: 90 days
Diabetes autoantibodies anti-GAD, anti-IA2, anti-ZnT8
units per milliliter (U/mL)
Time frame: 90 days
HbA1c
Millimoles of HbA1c per mole of hemoglobin (mmol/mol)
Time frame: 90 days
Quality of life questionnaire
Quality of life SF-12 v2 questionnaire, a higher score reflects higher quality of life
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.